We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ORKA

Price
11.68
Stock movement up
+0.39 (2.71%)
Company name
Oruka Therapeutics, Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
553.90M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-65.57%
3 year return
-20.03%
5 year return
-27.01%
10 year return
-36.79%
Last updated: 2025-09-15

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ORKA does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open14.95
Daily high14.99
Daily low14.10
Daily Volume181K
All-time high1000024.70
1y analyst estimate39.50
Beta-
EPS (TTM)-
Dividend per share-
Ex-div date29 Aug 2024
Next earnings date-

Downside potential

Loading...
Downside potential data
ORKAS&P500
Current price drop from All-time high-100.00%-1.46%
Highest price drop-100.00%-56.47%
Date of highest drop10 Apr 20259 Mar 2009
Avg drop from high-64.88%-10.99%
Avg time to new high5 days12 days
Max time to new high7052 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ORKA (Oruka Therapeutics, Inc.) company logo
Marketcap
553.90M
Marketcap category
Small-cap
Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Employees
28
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...